BrainsWay (BrainsWay) ROCE % : 9.51% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is BrainsWay ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BrainsWay's annualized ROCE % for the quarter that ended in Dec. 2023 was 9.51%.

BrainsWay ROCE % Historical Data

The historical data trend for BrainsWay's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrainsWay ROCE % Chart

BrainsWay Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-40.22

-17.16

-13.55

-21.12

-7.12

BrainsWay Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-32.14	-26.88	-10.27	-1.03	9.51

BrainsWay ROCE % Calculation

BrainsWay's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-3.898	/	( ( (64.477 - 8.141)	+	(62.972 - 9.761) )	/ 2 )
	=	-3.898	/	( (56.336	+	53.211)	/ 2 )
	=	-3.898	/	54.7735
	=	-7.12 %

BrainsWay's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	4.98	/	( ( (59.774 - 8.263)	+	(62.972 - 9.761) )	/ 2 )
	=	4.98	/	( ( 51.511	+	53.211 )	/ 2 )
	=	4.98	/	52.361
	=	9.51 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

BrainsWay (OTCPK:BRSYF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BrainsWay ROCE % Related Terms

Thank you for viewing the detailed overview of BrainsWay's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BrainsWay (BrainsWay) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BrainsWay Ltd (OTCPK:BRSYF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BWAY:USA BWAY:Israel

Address

19 Hartum Street, 3rd Floor, Bynet Building, Har Hotzvim, Jerusalem, ISR, 9777518

Website

https://www.brainsway.com

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.